A Review of Pharmacological Preconditioning for Hepatic Ischemia-Reperfusion Injury

  • Peiyang Qin Jinan University
  • Chi Huang Xiamen University
  • Tszching Sung Jinan University
DOI: https://doi.org/10.18686/aem.v11i3.239
Keywords: Ischemic Preconditioning, Ischemia-Reperfusion Injury, Hepatectomy, Liver Transplant, Drug

Abstract

Hepatic ischemia/reperfusion injury (HIRI) is a pathophysiological condition that occurs when the liver's blood supply is interrupted, resulting in organ hypoxia. It commonly happens when blood supply to the liver is reduced during liver resection due to prolonged obstruction of blood flow, shock, trauma, or heart failure. Prolonged hepatic ischemia followed by reperfusion, which occurs following a liver transplant, causes serious harm and contributes to increased morbidity and death. Several HIRI treatments, including pharmacological preconditioning, ischemic preconditioning, and remote ischemic preconditioning, have been proposed based on the further study on hepatic ischemia-reperfusion injury. Pharmacological preconditioning has demonstrated promising benefits in the prevention of liver injury in experimental models and a few randomised controlled human studies. The current state of pharmacological preconditioning for hepatic ischemia and reperfusion injury is discussed in this study.

References

[1] Mohammed SG., Ibrahim I, Mahmoud MF, & Mahmoud A. (2019). Carvedilol protects against hepatic ischemia/reperfusion injury in high-fructose/high-fat diet-fed mice: Role of G protein-coupled receptor kinase 2 and 5. Toxicology and applied pharmacology, 382, 114750.

[2] Ohana G, Cohen S, Rath-Wolfson L, & Fishman P. (2016). A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. Molecular medicine reports, 14(5), 4335–4341.

[3] Sherif IO, & Al-Shaalan NH. (2018). Vildagliptin Attenuates Hepatic Ischemia/Reperfusion Injury via the TLR4/NF-κB Signaling Pathway. Oxidative medicine and cellular longevity, 2018, 3509091.

[4] Abdel-Gaber SA, Geddawy A, & Moussa RA. (2019). The hepatoprotective effect of sitagliptin against hepatic ischemia reperfusion-induced injury in rats involves Nrf-2/HO-1 pathway. Pharmacological reports : PR, 71(6), 1044–1049.

[5] Yang Y, Chen C, Cui C, et al (2019). Indispensable role of β-arrestin2 in the protection of remifentanil preconditioning against hepatic ischemic reperfusion injury. Scientific reports, 9(1), 2087.

[6] Ye Y, Wang W, Zhang W. et al (2019). Galectin-1 attenuates hepatic ischemia reperfusion injury in mice. International immunopharmacology, 77, 105997.

[7] Kamel E O, Hassanein E, Ahmed MA, & Ali F. (2020). Perindopril Ameliorates Hepatic Ischemia Reperfusion Injury Via Regulation of NF-κB-p65/TLR-4, JAK1/STAT-3, Nrf-2, and PI3K/Akt/mTOR Signaling Pathways. Anatomical record (Hoboken, N.J. : 2007), 303 (7), 1935–1949.

[8] Yu Q, Wu L, Liu T, et al (2019). Protective effects of levo-tetrahydropalmatine on hepatic ischemia/reperfusion injury are mediated by inhibition of the ERK/NF-κB pathway. International immunopharmacology, 70, 435–445.
Published
2022-11-03
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Peiyang Qin

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.